Sorafenib Plus Temsirolimus Demonstrates Limited Benefit in Glioblastoma

Share this content:
Over 75% and 73.9% of VEGFi-naive and patients previously treated with a VEGFi, respectively, had at least 1 grade 3 or worse adverse event.
Over 75% and 73.9% of VEGFi-naive and patients previously treated with a VEGFi, respectively, had at least 1 grade 3 or worse adverse event.

Sorafenib and temsirolimus demonstrated limited activity with high rates of toxicity among patients with recurrent glioblastoma, according to a study published in Cancer.1

Sorafenib and temsirolimus target VEGFR-2 and mTOR, respectively, both of which are implicated in glioblastoma proliferation. For this phase 1/2 study (ClinicalTrials.gov Identifier: NCT00329719), patients were enrolled into a phase 1 dose-finding study or a phase 2 component. Eligible patients had recurrent glioblastoma after surgery or radiotherapy plus temozolomide and had previously received 2 or fewer systemic chemotherapy regimens.

The phase 1 study used a 3+3 dose escalation design to determine the maximum tolerated doses (MTDs) of sorafenib and temsirolimus. No dose-limiting toxicities (DLTs) were observed in patients at dose level 0 (sorafenib 200 twice daily and temsirolimus 25 mg weekly), but DLTs including grade 4 gastrointestinal perforation and grade 3 vomiting, nausea, and fatigue were observed once doses were increased to sorafenib 400 mg twice daily and temsirolimus 25 mg weekly.

In the phase 2 component, the median overall survival was 6.3 months vs 3.9 months for VEGFi-naive patients vs patients previously treated with a VEGFi, respectively.

Among the first 41 evaluable patients for phase 2, 7 patients (17.1%) in the VEGFi-naive arm had a progression-free survival (PFS) of 6 months and met the predetermined threshold for treatment success. Among patients previously treated with a VEGFi, only 4 patients (9.8%) of 41 had a PFS of 6 months, which did not meet the success threshold.

Over 75% and 73.9% of VEGFi-naive and prior VEGFi patients, respectively, had at least 1 grade 3 or worse adverse event.

The authors concluded that “significant dose reductions that were required in this treatment combination compared with tolerated single-agent doses may have contributed to the lack of efficacy.”

Reference

  1. Schiff D, Jaeckle KA, Anderson SK, et al. Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. Cancer. 2018 Jan 3. doi: 10.1002/cncr.31219 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs